ALK and lung adenocarcinoma: For example, in GENIE, patients with lung adenocarcinoma were first treated with Cisplatin/Pemetrexed or Cisplatin/Vinorelbine followed by diverse second line treatments which included EGFR-inhibitors (e.g., Erlotinib, Osimertinib, Afatinib), ALK-inhibitors (Alectinib/Crizotinib), Bevacizumab (anti-VEGF-antibody), Carboplatin, and immune checkpoint inhibitors (e.g., Pembrolizumab, Nivolumab, Durvalumab, Atezolizumab, and Ipilimumab).